Status: Not yet recruiting
RYZ711 Diagnostic Platform Study
This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomography/computed tomography (PET/CT) in men with histologically confirmed adenocarcinoma of the prostate.
Participants needed: 116
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: MaleType: InterventionalSponsor: RayzeBio, Inc.Updated: Oct 7, 2026
Eligibility criteria
Histologically confirmed adenocarcinoma of the prostate [+5]
eGFR < 60 mL/min, QTcF > 470 ms, impaired hepatic function [+5]